A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
Clinical trial NCT03086239 · COMPLETED
Trial details
- NCT number
- NCT03086239
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-28
- Primary completion
- 2018-01-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.